Viatris Korea and Jeil Pharmaceutical will launch the dyslipidemia treatment, Lipitor Plus (ingredients: atorvastatin and ezetimibe), on May 1.
Jeil Pharmaceutical received the Ministry of Food and Drug Safety’s approval for Lipitor Plus – 10/10 mg, 10/20 mg, and 10/40 mg -- on Feb. 18 to treat hypercholesterolemia and homozygous familial hypercholesterolemia.
Lipitor Plus is made of the same atorvastatin active pharmaceutical ingredient used in Lipitor (ingredient: atorvastatin). Viatris Korea will supply the active pharmaceutical ingredients for Jeil Pharmaceutical to manufacture the dyslipidemia compound.
The two companies plan to provide more tailored treatment options for Korean dyslipidemia patients by adding Lipitor Plus to the existing portfolio confirmed of the LDL-cholesterol-lowering effect and safety profile via large-scale global and domestic clinical trials, Viatris Korea said in a news release Tuesday.
“It is meaningful that we can create customized treatment environment for domestic dyslipidemia patients by adding therapeutic options on top of Lipitor, which has played a significant role in treating dyslipidemia and cardiovascular disease management in the clinical field,” Viatris Korea CEO Lee He-young and Jeil Pharmaceutical CEO Sung Seok-jae said.
The two CEOs added that the two companies would increase access to medicines by satisfying the needs of patients and health providers in a changing environment.
Viatris Korea was founded in November 2020 after Pfizer’s Upjohn business unit and global healthcare provider Mylan merged and formed a new company.